🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
02/06/2020 202,00 208,00 200,80 205,60 +2,39% 3,56% 118.829
01/06/2020 197,00 203,80 195,30 200,80 +4,86% 4,31% 87.816
29/05/2020 195,00 196,80 189,30 191,50 -2,25% 3,85% 205.393
28/05/2020 190,50 201,60 178,10 195,90 +3,11% 12,34% 377.964
27/05/2020 190,00 190,00 190,00 190,00 +0,00% 0,00% 0
26/05/2020 169,50 194,60 168,60 190,00 +29,60% 15,34% 585.109
25/05/2020 145,00 147,30 144,80 146,60 +0,89% 1,72% 28.448
22/05/2020 142,50 145,40 140,10 145,30 +1,18% 3,72% 98.001
21/05/2020 146,80 146,80 141,60 143,60 -2,31% 3,54% 114.295
20/05/2020 149,10 149,60 145,10 147,00 -2,07% 3,02% 127.649
19/05/2020 149,20 153,20 147,30 150,10 +1,01% 3,95% 101.443
18/05/2020 145,40 149,00 144,30 148,60 +4,43% 3,23% 88.920
15/05/2020 136,70 142,40 135,30 142,30 +6,43% 5,19% 73.431
14/05/2020 137,00 137,50 130,60 133,70 -2,69% 5,04% 79.222
13/05/2020 140,20 140,70 137,30 137,40 -4,05% 2,43% 66.253
12/05/2020 139,60 143,20 138,70 143,20 +2,87% 3,22% 53.683
11/05/2020 136,50 139,60 136,50 139,20 +2,13% 2,27% 66.282
08/05/2020 137,50 138,00 135,40 136,30 -0,29% 1,89% 28.701
07/05/2020 133,20 136,70 133,20 136,70 +3,25% 2,63% 41.710
06/05/2020 134,60 135,70 132,20 132,40 -1,19% 2,60% 53.539
05/05/2020 136,00 137,80 133,10 134,00 -0,22% 3,46% 47.943
04/05/2020 135,50 136,80 133,20 134,30 -2,33% 2,66% 46.844
30/04/2020 137,10 140,30 135,80 137,50 +1,55% 3,28% 54.227
29/04/2020 136,00 136,10 133,00 135,40 +0,30% 2,28% 38.512
28/04/2020 137,00 137,10 133,50 135,00 -0,74% 2,63% 34.508
27/04/2020 137,50 138,60 135,70 136,00 +0,29% 2,11% 32.777
24/04/2020 132,50 135,60 131,00 135,60 +1,95% 3,47% 30.599
23/04/2020 134,00 135,90 132,50 133,00 -0,82% 2,54% 43.848
22/04/2020 132,80 134,70 132,50 134,10 +1,44% 1,66% 24.757
21/04/2020 135,00 135,50 132,00 132,20 -2,94% 2,59% 45.027